Pyramid Labs Retatrutide 10mg is a high-purity research-grade triple hormone receptor agonist peptide (also known as LY3437943). This innovative single-molecule compound simultaneously activates the GLP-1, GIP, and glucagon receptors, delivering multi-pathway metabolic regulation that goes beyond dual agonists. It is supplied as a lyophilized research peptide for advanced studies in obesity, type 2 diabetes, energy expenditure, and cardiometabolic health.
Key Benefits:
- Substantial body weight reduction — clinical research has shown mean losses of up to 24.2% at 48 weeks and approximately 28% (or more in longer trials) at higher doses, ranking among the most robust results reported for once-weekly injectables.
- Improved glycemic control with significant reductions in HbA1c (up to ~2%) and fasting glucose levels.
- Enhanced energy expenditure and fat metabolism driven by glucagon receptor agonism, alongside appetite suppression and delayed gastric emptying from GLP-1 activity.
- Meaningful decreases in waist circumference, BMI, and visceral adiposity.
- Favorable effects on liver fat (substantial relative reductions reported in metabolic dysfunction-associated steatotic liver disease models).
- Improvements in cardiometabolic markers including triglycerides, non-HDL cholesterol, blood pressure, and inflammatory markers such as hs-CRP.
- Potential supportive research applications in related areas such as knee osteoarthritis symptoms and obstructive sleep apnea.
Retatrutide represents a next-generation approach in metabolic peptide research by combining incretin-mediated satiety and insulinotropic effects with glucagon-driven thermogenesis and hepatic fat oxidation. Ideal for laboratories investigating multi-agonist strategies for obesity, diabetes, and adipose tissue remodeling. Research use only.
Reviews
There are no reviews yet.